SCHEMBL10004349

SCHEMBL10004349

CCOC(=O)c1c(OCC(F)(F)F)c2nc(NC(=O)c3ccccc3)c(CC)nc2n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.44
▸ PDE4B Q07343 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.39
▸ HPGD P15428 2/20 0.39
▸ SMN1; SMN2 Q16637 5/20 0.39
▸ RAB9A P51151 5/20 0.39
▸ NPC1 O15118 4/20 0.39
▸ GAA P10253 1/20 0.39
▸ ADORA2A P29274 3/20 0.39
▸ ADORA1 P30542 3/20 0.39
▸ ADORA3 P0DMS8 2/20 0.38
▸ DHODH Q02127 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ LMNA P02545 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ P2RX3 P56373 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003290 0.92 P2RX3 (0.35) HTTALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL10003086 0.91 HTT (0.45) HTTPDE4BALDH1A1HPGDSMN1; SMN2
SCHEMBL10003034 0.85 HTT (0.44) HTTPDE4BALDH1A1HPGDSMN1; SMN2
SCHEMBL10003336 0.84 SMN1; SMN2 (0.41) HTTPDE4BALDH1A1HPGDSMN1; SMN2
SCHEMBL10003837 0.84 GABRA2 (0.43) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL10003477 0.83 HTT (0.47) HTTPDE4BALDH1A1HPGDSMN1; SMN2
SCHEMBL10004000 0.83 P2RX3 (0.41) HTTALDH1A1RAB9ANPC1ADORA2A
SCHEMBL10003483 0.81 SMO (0.57) —
SCHEMBL16588414 0.79 SMO (0.50) LMNA
SCHEMBL16070729 0.79 SMO (0.48) MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH HTT 3635/4885PDE4B 368/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback